Bilateral Pleural EffusionNCT07810049
Synchronous Bilateral Talc Pleurodesis
An observational study of Bilateral Pleural Effusion and Pleurodesis, run by European Institute of Oncology at 1 site in Italy.
Trial summary
Investigate feasibility of synchronous bilateral talc pleurodesis for malignant bilateral pleural effusions Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bilateral Pleural Effusion, Pleurodesis
- How many people
- 31 participants
- Where
- 1 siteItaly
- Study dates
- Jan 1998to 30 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patient diagnosed with malignant pleural bilateral effusion
Who may be able to join
- Age ≥ 18 year-old
- Patients undergoing synchronous bilateral talc pleurodesis
- Diagnosis of malignant bilateral pleural effusions
- Surgical resection between 1998 and September 2025
Who cannot join
- Other type of surgery
- Lack of consent to research
- Other type of diagnosis (e.g. viral disease)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Synchronous Bilateral Talc Pleurodesis for Malignant Bilateral Pleural Effusions
Investigate feasibility of synchronous bilateral talc pleurodesis for malignant bilateral pleural effusions
- Conditions
- Bilateral Pleural Effusion, Pleurodesis
- Keywords
- lung cancer, malignant pleural effusion, pleurodesis, bilateral pleural effusion
- Medical subject headings
- Lung Neoplasms, Pleural Effusion, Malignant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patient diagnosed of malignant bilateral pleural effusions | Patient diagnosed of malignant bilateral pleural effusions that underwent a synchronous bilateral talc pleurodesis |
What is being measured
The primary outcome is the main question the study is designed to answer.
postoperative mortality
Evaluation of postoperative complications occurred after talc pleurodesis.
Measured: 35 years
postoperative morbidity
Evaluation of postoperative complications occurred after talc pleurodesis.
Measured: 35 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study startJan 1998
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bilateral Pleural EffusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- European Institute of Oncology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07810049
- Sponsor's protocol ID
- UID 5221
- Other IDs
- L2-515
- Status last verified
- Jan 2026
- First submitted
- 15 Jan 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Synchronous Bilateral Talc Pleurodesis for Malignant Bilateral Pleural Effusions
- ClinicalTrials.gov ID
- NCT07810049
- Acronym / sponsor ID
- UID 5221
- Conditions
- Bilateral Pleural Effusion, Pleurodesis
- Keywords
- lung cancer, malignant pleural effusion, pleurodesis, bilateral pleural effusion
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- European Institute of OncologyUniversity, hospital or other
- Study start
- Jan 1998 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 9 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigate feasibility of synchronous bilateral talc pleurodesis for malignant bilateral pleural effusions
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient diagnosed of malignant bilateral pleural effusions | – | –Patient diagnosed of malignant bilateral pleural effusions that underwent a synchronous bilateral talc pleurodesis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patient diagnosed with malignant pleural bilateral effusion
Key inclusion criteria (4 listed)
- Age ≥ 18 year-old
- Patients undergoing synchronous bilateral talc pleurodesis
- Diagnosis of malignant bilateral pleural effusions
- Surgical resection between 1998 and September 2025
Key exclusion criteria (3 listed)
- Other type of surgery
- Lack of consent to research
- Other type of diagnosis (e.g. viral disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
postoperative mortality
Time frame: 35 years
Evaluation of postoperative complications occurred after talc pleurodesis.
postoperative morbidity
Time frame: 35 years
Evaluation of postoperative complications occurred after talc pleurodesis.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bilateral Pleural Effusion and Pleurodesis, run by European Institute of Oncology at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
postoperative mortality (time frame: 35 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.